Surfactants and peptide stability

Surfactants are often assumed to protect biologic medicines from damage at air, liquid and container surfaces. A new laboratory study shows why that shortcut does not safely transfer to therapeutic peptides. Under agitation stress, polysorbate 80 and poloxamer 188 increased aggregation and structural change in liraglutide, while semaglutide changed much less and surfactants did not stop glucagon fibrillation^[1]. The useful takeaway is not that one additive is good or bad. It is that peptide stability depends on the individual molecule, the interface it encounters, and the conditions used to test it.

What the study examined

Hamada and colleagues used liraglutide as the main model peptide, then looked at semaglutide and glucagon under agitation stress. They tested polysorbate 80, polysorbate 20 and poloxamer 188, three surfactants used in pharmaceutical formulation work. The team measured conformational change, oligomerization and aggregation with size-exclusion chromatography, circular dichroism and nuclear magnetic resonance^[1]. This was a controlled formulation experiment, not a clinical trial and not a comparison of treatments.

The results differed by peptide. Liraglutide formed dynamic oligomers that were not stable during agitation. Polysorbate 80 and poloxamer 188 were associated with extensive aggregation and structural rearrangement, with faster aggregation reported for polysorbate 80. The authors found evidence of a strong, specific liraglutide and polysorbate 80 interaction, while the pattern with poloxamer 188 pointed instead to an interfacial mechanism^[1].

Why an interface can matter

An interface is simply a boundary where two materials meet, such as air and liquid or liquid and a container surface. Agitation creates and refreshes those boundaries. For a flexible peptide, contact at that boundary can change how molecules meet each other. Sometimes a surfactant can occupy part of the interface. In this study, though, the outcome depended on the peptide and the surfactant rather than following one universal rule^[1].

That is one reason a formulation result should not be turned into a consumer rule. The paper studied defined materials under a defined stress condition. It did not test home handling, assess a particular device, or show that an additive changes a clinical outcome. It also did not provide a basis for changing any prescribed medicine. Readers looking for the broader biology can start with our semaglutide overview, which separates the medicine from the formulation question discussed here.

Semaglutide was less affected in this experiment

Semaglutide showed limited changes in aggregation behavior in the presence of the tested surfactants. The authors linked that contrast with its more stable oligomers. Glucagon had a strong intrinsic tendency to fibrillate, and the surfactants modestly changed aggregation rates without preventing fibril formation^[1]. Those findings are useful for understanding the experiment, but they do not rank medicines by safety, effectiveness or suitability for an individual person.

Semaglutide is a GLP-1 receptor agonist in approved prescription products. The FDA label describes the active ingredient and its formulation for a specific approved product, which is a different evidence category from a stress experiment involving a model formulation^[2]. If you are trying to distinguish the drug class from research around specific molecules, our semaglutide explainer provides that context.

What this says about peptide quality

The paper supports a narrow but important point: a peptide cannot be treated as a miniature monoclonal antibody, and a surfactant cannot be treated as a universal stabilizer. The authors argue that the relevant balance includes peptide to peptide interactions, peptide to surfactant interactions, surfactant-mediated interfacial stress and the inherent stability of the peptide oligomers^[1]. A useful stability assessment therefore needs a method that is appropriate for the molecule and the question being asked.

It also puts a limit on what can be inferred from a product description or a purity number alone. Neither tells a reader how a particular peptide behaved during a particular stress study. The distinction matters especially when claims about peptide products outpace the underlying analytical evidence. Method details, stress conditions and the measurement used are part of the evidence, not optional background.

What we do not yet know

This single study does not establish how every therapeutic peptide behaves, whether the same pattern appears in every finished product, or what the findings mean for a patient outcome. It focused on three peptides, three surfactants and agitation stress. The authors also describe commercial parenteral peptide use of surfactants as selective and note that the rationale remains unclear^[1]. More work is needed before a general formulation rule can be claimed.

The practical boundary is straightforward. Do not use a laboratory aggregation paper to alter storage, handling or treatment decisions. Approved products have their own official instructions and clinical context. If you have a question about a prescribed peptide medicine, discuss it with the clinician or pharmacist responsible for that medicine. For regulatory context around semaglutide in the United States, see our United States semaglutide status page.